Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma

NCT06194656 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

81

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: HER3 Monoclonal antibodies-Dose A
DRUG: HER3 Monoclonal antibodies-Dose B
DRUG: HER3 Monoclonal antibodies-Dose C
OTHER: HER3 Monoclonal antibodies-Dose D
OTHER: Placebo
COMBINATION_PRODUCT: Cetuximab injection

Sponsor

Shanghai Institute Of Biological Products